## Wing-Kin Syn

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1420840/publications.pdf

Version: 2024-02-01

83	3,999	29 h-index	61
papers	citations		g-index
86	86	86	6192 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014, 59, 1174-1197.	7.3	478
2	Nonâ€alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International Journal of Cancer, 2011, 128, 2436-2443.	5.1	425
3	Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. Journal of Clinical Investigation, 2008, 118, 3331-42.	8.2	284
4	Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1998-2007.	7.3	254
5	Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2009, 137, 1478-1488.e8.	1.3	232
6	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut, 2012, 61, 1323-1329.	12.1	231
7	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology, 2011, 53, 106-115.	7.3	224
8	Vitamin D counteracts fibrogenic TGF- $\hat{l}^2$ signalling in human hepatic stellate cells both receptor-dependently and independently. Gut, 2015, 64, 791-799.	12.1	118
9	Hedgehog regulates yesâ€associated protein 1 in regenerating mouse liver. Hepatology, 2016, 64, 232-244.	7.3	94
10	Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 93-108.A.	7.4	84
11	Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. Clinical Gastroenterology and Hepatology, 2015, 13, 1836-1842.e2.	4.4	83
12	Osteopontin—A Master Regulator of Epithelial-Mesenchymal Transition. Journal of Clinical Medicine, 2016, 5, 39.	2.4	80
13	Human intrahepatic regulatory T cells are functional, require ILâ€2 from effector cells for survival, and are susceptible to Fas ligandâ€mediated apoptosis. Hepatology, 2016, 64, 138-150.	7.3	72
14	Hepatokines and adipokines in NASH-related hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 442-457.	3.7	72
15	Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis. Frontiers in Cell and Developmental Biology, 2018, 6, 150.	3.7	63
16	Role for hedgehog pathway in regulating growth and function of invariant NKT cells. European Journal of Immunology, 2009, 39, 1879-1892.	2.9	59
17	Serum Interleukinâ€8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2018, 2, 1344-1355.	4.3	58
18	TWEAK/Fn14 Signaling Is Required for Liver Regeneration after Partial Hepatectomy in Mice. PLoS ONE, 2014, 9, e83987.	2.5	58

#	Article	IF	Citations
19	Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. American Journal of the Medical Sciences, 2017, 354, 172-181.	1.1	56
20	Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. PLoS ONE, 2017, 12, e0185902.	2.5	54
21	Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2018, 63, 3187-3206.	2.3	53
22	Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs, 2019, 79, 903-927.	10.9	47
23	Similarities and Differences in the Pathogenesis of Alcoholic and Nonalcoholic Steatohepatitis. Seminars in Liver Disease, 2009, 29, 200-210.	3.6	46
24	Role of liver progenitors in acute liver injury. Frontiers in Physiology, 2013, 4, 258.	2.8	41
25	Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells, 2020, 9, 2458.	4.1	40
26	Endoscopic management is the treatment of choice for bile leaks after liver resection. Gastrointestinal Endoscopy, 2014, 80, 626-633.e1.	1.0	39
27	Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 135-144.	3.8	39
28	Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2019, 64, 2351-2358.	2.3	35
29	Iron Enhances Hepatic Fibrogenesis and Activates Transforming Growth Factor-β Signaling in Murine Hepatic Stellate Cells. American Journal of the Medical Sciences, 2018, 355, 183-190.	1.1	32
30	Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Clinical Science, 2015, 129, 875-883.	4.3	29
31	Genetic differences in oxidative stress and inflammatory responses to dietâ€induced obesity do not alter liver fibrosis in mice. Liver International, 2009, 29, 1262-1272.	3.9	26
32	Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. PLoS ONE, 2016, 11, e0162286.	2.5	25
33	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterology, 2018, 9, 115-121.	1.8	23
34	Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clinical Science, 2014, 126, 845-855.	4.3	22
35	NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?. Visceral Medicine, 2016, 32, 234-238.	1.3	22
36	Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E131-E144.	3.5	22

#	Article	IF	Citations
37	Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. Nature Communications, 2022, 13, 1096.	12.8	22
38	Mini-Laparoscopy Guided Liver Biopsy Increases Diagnostic Accuracy in Acute Liver Failure. Digestion, 2014, 90, 240-247.	2.3	21
39	Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment. Cancer Letters, 2018, 419, 175-186.	7.2	21
40	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Bioscience Reports, 2020, 40, .	2.4	21
41	The motor protein Myo1c regulates transforming growth factor-β–signaling and fibrosis in podocytes. Kidney International, 2019, 96, 139-158.	5.2	20
42	Liver osteopontin is required to prevent the progression of ageâ€related nonalcoholic fatty liver disease. Aging Cell, 2020, 19, e13183.	6.7	20
43	Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. Journal of Lipid Research, 2017, 58, 1903-1915.	4.2	18
44	Role of liver progenitors in liver regeneration. Hepatobiliary Surgery and Nutrition, 2015, 4, 48-58.	1.5	18
45	Gene expression profiling in bladder cancer identifies potential therapeutic targets. International Journal of Oncology, 2017, 50, 1147-1159.	3.3	17
46	Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. European Journal of Nutrition, 2019, 58, 1785-1800.	3.9	17
47	Low Levels of Blood Lipids Are Associated with Etiology and Lethal Outcome in Acute Liver Failure. PLoS ONE, 2014, 9, e102351.	2.5	17
48	Higher Thyroid-Stimulating Hormone, Triiodothyronine and Thyroxine Values Are Associated with Better Outcome in Acute Liver Failure. PLoS ONE, 2015, 10, e0132189.	2.5	14
49	Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology, 2019, 35, 168-176.	2.3	14
50	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. Hepatology, 2021, 74, 2561-2579.	7.3	13
51	GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E30-E42.	3.5	12
52	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2021, 66, 3676-3688.	2.3	11
53	Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni. International Journal for Parasitology, 2016, 46, 829-832.	3.1	9
54	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. Journal of Clinical Medicine, 2021, 10, 1507.	2.4	9

#	Article	IF	CITATIONS
55	Differential osteopontin functions: The role of osteopontin isoforms. Hepatology, 2015, 62, 323-324.	7.3	7
56	Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni. PLoS Neglected Tropical Diseases, 2016, 10, e0005057.	3.0	7
57	Prediction of transcription factor bindings sites affected by SNPs located at the osteopontin promoter. Data in Brief, 2017, 14, 538-542.	1.0	7
58	Anti‶NFα treatment in Crohn's disease: Impact on hepatic steatosis, gutâ€derived hormones and metabolic status. Liver International, 2021, 41, 2646-2658.	<sup>C</sup> 3.9	7
59	Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice. Scientific Reports, 2016, 6, 36586.	3.3	6
60	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. Digestive Diseases and Sciences, 2019, 64, 3394-3401.	2.3	6
61	Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?. Gut, 2020, 69, 975-976.	12.1	6
62	Repair-associated inflammation in nonalcoholic fatty liver disease. Clinical Medicine, 2013, 13, s15-s19.	1.9	5
63	Characteristics of amino acid substitutions within the "a―determinant region of hepatitis B virus in chronically infected patients with coexisting HBsAg and anti-HBs. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 923-931.	1.5	5
64	Targeting myosin 1c inhibits murine hepatic fibrogenesis. American Journal of Physiology - Renal Physiology, 2021, 320, G1044-G1053.	3.4	5
65	Utility of Osteopontin in Lineage Tracing Experiments. Gastroenterology, 2013, 145, 254-255.	1.3	4
66	The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related?. Digestive Diseases and Sciences, 2020, 65, 1885-1887.	2.3	4
67	<p>Association of <em>IFNL3</em> rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population</p> . Clinical and Experimental Gastroenterology, 2019, Volume 12, 433-439.	2.3	3
68	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. Open Forum Infectious Diseases, 2018, 5, ofy138.	0.9	2
69	A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver. Metabolites, 2022, 12, 130.	2.9	2
70	The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. Scientific Reports, 2022, 12, 5123.	3.3	2
71	Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)â€"cause for concern?. Hepatobiliary Surgery and Nutrition, 2018, 7, 138-142.	1.5	1
72	Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice. Scientific Reports, 2018, 8, 14626.	3.3	1

#	Article	IF	CITATIONS
73	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease–Targeting Primary Care Physicians. Diabetes Technology and Therapeutics, 2019, 21, 611-618.	4.4	1
74	NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease. Digestive Diseases and Sciences, 2021, 66, 2147-2148.	2.3	1
75	Sa1003 ACCURACY OF FIBROSCAN CONTINUOUS ATTENUATION PARAMETER AND LIVER STIFFNESS IN ASSESSING STEATOSIS AND FIBROSIS IN USA VETERANS WITH NONALCOHOLIC FATTY LIVER DISEASE. Gastroenterology, 2020, 158, S-237.	1.3	1
76	Pathogenic Mechanisms in Alcoholic Liver Disease (ALD): Emerging Role of Osteopontin., 2016, , 63-70.		1
77	Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD. Clinical and Experimental Gastroenterology, 2022, Volume 15, 1-3.	2.3	1
78	Profile of drug resistance mutations in nucleos(t)ide analogue-experienced chronic hepatitis B patients in Tianjin, China. International Journal of Antimicrobial Agents, 2018, 52, 735-736.	2.5	0
79	THU-315-Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness. Journal of Hepatology, 2019, 70, e299.	3.7	0
80	FRI-356-Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight. Journal of Hepatology, 2019, 70, e551-e552.	3.7	0
81	Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth. Digestive Diseases and Sciences, 2019, 64, 606-608.	2.3	0
82	Su336 UTIILTY OF THE FASTâ,,¢ SCORE IN IDENTIFYING US VETERANS WITH HIGH RISK NONALCOHOLIC STEATOHEPATITIS (NASH): A VALIDATION STUDY. Gastroenterology, 2021, 160, S-669.	1.3	0
83	STARD1: a new rising StAR in cholesterol-mediated hepatocarcinogenesis. Hepatobiliary Surgery and Nutrition, 2021, 10, 910-912.	1.5	O